Generic Wynzora Availability
Last updated on May 7, 2025.
Wynzora is a brand name of betamethasone/calcipotriene topical, approved by the FDA in the following formulation(s):
WYNZORA (betamethasone dipropionate; calcipotriene - cream;topical)
-
Manufacturer: MC2
Approval date: July 20, 2020
Strength(s): 0.064%;0.005% [RLD]
Is there a generic version of Wynzora available?
No. There is currently no therapeutically equivalent version of Wynzora available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Wynzora. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical composition
Patent 10,265,265
Issued: April 23, 2019
Inventor(s): Wheeler Derek & Steele David F. & Georgiou Michelle & Sindet-Pedersen Steen
Assignee(s): DRUG DELIVERY SOLUTIONS LIMITEDA composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analog and at least one corticosteroid.
Patent expiration dates:
- September 27, 2027✓
- September 27, 2027
-
Topical composition
Patent 11,696,919
Issued: July 11, 2023
Inventor(s): Crutchley; Nigel et al.
Assignee(s): MC2 Therapeutics Limited (Guildford, GB)The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
Patent expiration dates:
- March 18, 2039✓
- March 18, 2039
More about Wynzora (betamethasone / calcipotriene topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical antipsoriatics
- En español
Patient resources
Other brands
Enstilar, Taclonex, Taclonex Scalp
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
